Elsabagh Ahmed Adel, Elhadary Mohamed, Elsayed Basel, Elshoeibi Amgad Mohamed, Ferih Khaled, Kaddoura Rasha, Alkindi Salam, Alshurafa Awni, Alrasheed Mona, Alzayed Abdullah, Al-Abdulmalek Abdulrahman, Altooq Jaffer Abduljabber, Yassin Mohamed
College of Medicine, QU Health, Qatar University, Doha, Qatar.
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Blood Rev. 2023 Sep;61:101102. doi: 10.1016/j.blre.2023.101102. Epub 2023 Jun 8.
Artificial intelligence (AI) is rapidly becoming an established arm in medical sciences and clinical practice in numerous medical fields. Its implications have been rising and are being widely used in research, diagnostics, and treatment options for many pathologies, including sickle cell disease (SCD). AI has started new ways to improve risk stratification and diagnosing SCD complications early, allowing rapid intervention and reallocation of resources to high-risk patients. We reviewed the literature for established and new AI applications that may enhance management of SCD through advancements in diagnosing SCD and its complications, risk stratification, and the effect of AI in establishing an individualized approach in managing SCD patients in the future. Aim: to review the benefits and drawbacks of resources utilizing AI in clinical practice for improving the management for SCD cases.
人工智能（AI）正迅速成为众多医学领域医学科学和临床实践中的既定力量。其影响不断增加，并广泛应用于包括镰状细胞病（SCD）在内的多种病症的研究、诊断和治疗选择中。人工智能开创了新方法，以改善风险分层并早期诊断SCD并发症，从而能够迅速进行干预，并将资源重新分配给高危患者。我们查阅了相关文献，以了解已确立的和新的人工智能应用，这些应用可能通过在诊断SCD及其并发症方面的进展、风险分层以及人工智能在未来建立个性化SCD患者管理方法方面的作用，来加强SCD的管理。目的：回顾在临床实践中利用人工智能资源改善SCD病例管理的利弊。
